MedTechBiopharmaMedtech
J.P. Morgan Reports Strong Biopharma and Medtech Investment in First Half of 2026
By MedXY|Jul 29, 2026
J.P. Morgan reports show biopharma and medtech investment remained strong in H1 2026, with licensing, M&A, venture funding, and IPOs all showing resilience, though investors favored later-stage assets.